Mankind Pharma Valuation
Is MANKIND undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MANKIND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MANKIND (₹2558.65) is trading above our estimate of fair value (₹1412.68)
Significantly Below Fair Value: MANKIND is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MANKIND?
Key metric: As MANKIND is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is MANKIND's PE Ratio? | |
|---|---|
| PE Ratio | 48.5x |
| Earnings | ₹21.15b |
| Market Cap | ₹1.03t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.9x |
| Enterprise Value/EBITDA | 36.1x |
| PEG Ratio | 3.1x |
Price to Earnings Ratio vs Peers
How does MANKIND's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.7x | ||
500420 Torrent Pharmaceuticals | 58.3x | 22.7% | ₹1.1t |
500124 Dr. Reddy's Laboratories | 18.7x | -1.0% | ₹995.0b |
ZYDUSLIFE Zydus Lifesciences | 22.2x | 0.6% | ₹949.9b |
500257 Lupin | 35.5x | 16.4% | ₹932.1b |
MANKIND Mankind Pharma | 48.5x | 15.4% | ₹1.0t |
Price-To-Earnings vs Peers: MANKIND is expensive based on its Price-To-Earnings Ratio (48.5x) compared to the peer average (33.7x).
Price to Earnings Ratio vs Industry
How does MANKIND's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.6x | n/a | US$71.82m |
524652 Ind-Swift | 2x | n/a | US$13.29m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: MANKIND is expensive based on its Price-To-Earnings Ratio (48.5x) compared to the Indian Pharmaceuticals industry average (32.2x).
Price to Earnings Ratio vs Fair Ratio
What is MANKIND's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 48.5x |
| Fair PE Ratio | 45.8x |
Price-To-Earnings vs Fair Ratio: MANKIND is expensive based on its Price-To-Earnings Ratio (48.5x) compared to the estimated Fair Price-To-Earnings Ratio (45.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹2,558.65 | ₹2,814.88 +10.0% | 11.9% | ₹3,300.00 | ₹2,275.00 | n/a | 16 |
| Nov ’25 | ₹2,680.70 | ₹2,469.87 -7.9% | 15.2% | ₹3,300.00 | ₹1,900.00 | n/a | 15 |
| Oct ’25 | ₹2,578.95 | ₹2,445.07 -5.2% | 14.9% | ₹3,300.00 | ₹1,900.00 | n/a | 15 |
| Sep ’25 | ₹2,487.75 | ₹2,297.57 -7.6% | 10.1% | ₹2,760.00 | ₹1,900.00 | n/a | 14 |
| Aug ’25 | ₹2,004.75 | ₹2,289.71 +14.2% | 9.5% | ₹2,650.00 | ₹1,900.00 | n/a | 14 |
| Jul ’25 | ₹2,160.85 | ₹2,302.87 +6.6% | 10.3% | ₹2,650.00 | ₹1,800.00 | n/a | 15 |
| Jun ’25 | ₹2,139.75 | ₹2,266.93 +5.9% | 9.8% | ₹2,554.00 | ₹1,800.00 | n/a | 14 |
| May ’25 | ₹2,364.40 | ₹2,199.77 -7.0% | 10.9% | ₹2,520.00 | ₹1,750.00 | n/a | 13 |
| Apr ’25 | ₹2,311.90 | ₹2,197.69 -4.9% | 10.9% | ₹2,520.00 | ₹1,750.00 | n/a | 13 |
| Mar ’25 | ₹2,149.35 | ₹2,184.17 +1.6% | 11.2% | ₹2,520.00 | ₹1,750.00 | n/a | 12 |
| Feb ’25 | ₹2,046.25 | ₹1,937.73 -5.3% | 13.0% | ₹2,300.00 | ₹1,433.00 | n/a | 11 |
| Jan ’25 | ₹1,979.20 | ₹1,859.00 -6.1% | 10.7% | ₹2,140.00 | ₹1,433.00 | n/a | 11 |
| Dec ’24 | ₹1,914.00 | ₹1,859.00 -2.9% | 10.7% | ₹2,140.00 | ₹1,433.00 | n/a | 11 |
| Nov ’24 | ₹1,743.60 | ₹1,853.73 +6.3% | 11.0% | ₹2,190.00 | ₹1,433.00 | ₹2,680.70 | 11 |
| Oct ’24 | ₹1,795.30 | ₹1,817.82 +1.3% | 12.9% | ₹2,180.00 | ₹1,433.00 | ₹2,578.95 | 11 |
| Sep ’24 | ₹1,716.55 | ₹1,838.60 +7.1% | 12.8% | ₹2,180.00 | ₹1,433.00 | ₹2,487.75 | 10 |
| Aug ’24 | ₹1,771.20 | ₹1,626.30 -8.2% | 10.0% | ₹1,875.00 | ₹1,425.00 | ₹2,004.75 | 10 |
| Jul ’24 | ₹1,706.80 | ₹1,648.67 -3.4% | 9.5% | ₹1,875.00 | ₹1,429.00 | ₹2,160.85 | 9 |
| Jun ’24 | ₹1,395.40 | ₹1,484.50 +6.4% | 3.1% | ₹1,539.00 | ₹1,429.00 | ₹2,139.75 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Bal Pharma
₹2.2b
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.
BALPHARMA
₹134.50
7D
11.6%
1Y
27.4%
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹911.45
7D
-3.5%
1Y
18.7%
Caplin Point Laboratories
₹147.7b
Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.
CAPLIPOINT
₹1,942.80
7D
-0.4%
1Y
58.1%